Risk factor
Good trading liquidity
Profitability factor
Favourable analyst view
About
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It...
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITDA, reasonably pr
Target Price
The average target price of PHARM.AS is 2.3 and suggests 74% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Buy
Sell